Over 18 years of experience in clinical research and 9 years in digital CRO. Holds an MBA from The University of Hong Kong and is a pioneer in decentralized clinical trial (DCT) practices in China.
Previously worked at world-renowned companies such as Roche, PPD, and Chiltern, leading multiple large-scale regional studies as the China lead, managing projects across nearly 150 research sites.
Key Contributions: Co-author of *Real-World Research Guidelines 2018*; Co-author of Medical Code in the AI Era; Co-author of Blue Book on Remote & Intelligent Clinical Trials; Committee member of DIA (Drug Information Association), involved in oncology researcher training programs.
18余年临床研究领域经验，9余年医疗数字化创业经历。香港大学工商管理学硕士，DCT中国临床研究实践的先行者。
曾就职于罗氏、PPD、Chiltern等世界知名企业，参与多项大型regional study 任中国区负责人，负责近150家研究中心的项目管理工作。《真实世界研究指南2018 》执笔专家之一, 《AI时代医学密码》执笔专家之一，《远程智能临床试验蓝皮书》执笔专家之一，同时担任DIA组委会成员参与肿瘤研究者培训工作。
Dr. Li ZENG joined Jing Medicine as Chief Executive Officer in November 2021, bringing with him a wealth of R&D and business operation experience in the pharmaceutical industry with a career spanning over 18 years. He has held drug R&D, portfolio and project management positions of increasing responsibilities in multinational companies such as Novartis and Eli Lilly as well as in traditional local pharma and biotech firms such as Luoxin Pharmaceutical, 4B Technologies and Harbour Biomed.
Dr. Zeng received his bachelor’s degree in chemistry from Peking University and Ph.D. in Organic Chemistry from Stanford University. He conducted his postdoctoral research training in Chemical Biology at University of California, Berkeley.
曾雳博士于2021年11月加入和径医药担任首席执行官，拥有超过19年的新药研发和管理经验。曾博士先后在跨国药企诺华公司和礼来公司负责新药研发和项目管理，以及在罗欣药业、福贝生物和和铂医药等民营企业和生物技术公司负责战略规划和运营、新药产品线和项目管理。
曾博士分别在北京大学和斯坦福大学获得化学学士和有机化学博士学位，并在加州大学伯克利分校完成化学生物学的博士后训练。
Jasper Morley, senior Drugs Intelligence Analyst at GlobalData. His primary responsibilities include managing and maintaining GlobalData’s Drugs Database, analyzing marketed drug information, and producing analytical market insight reports. In addition, Jasper provides timely client support and performs database quality checks. Prior to joining GlobalData, Jasper worked as a Medical Affairs associate at Merz Pharma UK, focusing on Medical Information and Pharmacovigilance activities within the neurology and dermatology therapy areas. More recently, Jasper was employed by the University College London Hospitals NHS Foundation Trust, working within the research facilities of the Cancer Clinical Trials Unit.
Laurent’s career, grounded in organic chemistry, shifted to peptide synthesis during his 2005 postdoctoral work in Manchester. He joined Cambridge Research Biochemicals, later acquired by Biosynth, as a peptide chemist, gaining hands-on experience in synthesis, purification, and dye-labelling.
Progressing over 17 years, he advanced to managing peptide chemists and production, ultimately becoming a Site Manager and Operational lead, driving scientific development with a focus on novel peptide synthesis methodologies. Laurent now serves as Biosynth’s Market Development Specialist for Peptides, a pivotal role in expanding the company’s custom and GMP peptide business. He is instrumental in optimizing the project portfolio and enhancing Biosynth’s technical and commercial offerings to meet strategic financial and commercial objectives.
Julia Wittmann holds a diploma in Biology from Georg-August-Universität Göttingen, specializing in Genetics, Microbiology, and Physical Chemistry. Her diploma thesis focused on the molecular biological construction and analysis of a chimeric protein in E. coli. She completed her Ph.D. at the same institution, with research on the targeted modification and binding properties of proteins from
Escherichia coli and Saccharomyces cerevisiae. Since 2003, Dr. Wittmann has served as a scientific researcher in the Department of Molecular Structural Biology at the Institute for Microbiology and Genetics, within Dr. Markus Rudolph’s group. Her background also includes experience in a medical analysis laboratory and scientific consulting, encompassing patent research and market analysis.
Hansjoerg Streicher studied organic chemistry at the University of Konstanz, Germany, with a focus on carbohydrates, glycoscience, and synthesis. After a period as a visiting scientist at the Weizmann Institute of Science, Israel, he became a Lecturer in Chemistry and Chemical Biology at the University of Sussex, where he taught and conducted research for eight years. Hans later moved into consultancy, providing expertise in synthetic chemistry and intellectual property before joining Biosynth as a Senior Scientific Advisor. His work supports project teams in glycoscience and organic synthesis, where he continues to contribute to technical marketing and research initiatives.
Scott Miller, is our new Senior Director of R&D. Scott brings experience from previous roles at CARBOGEN AMCIS AG, Adolor Corporation, Cephalon and Hovione. He holds a 1990 – 1992 Postdoctoral Fellow in Chemistry from ETH Zürich. Scott boasts a robust skill set that includes project management, cGMP manufacturing, chemistry process research and development from preclinical through validation, as well as CMC IND, ANDA, and NDA filings.
Bertrand Chataing is Director of Corporate Sales at autobiz, bringing over 15 years of experience in the automotive and financial services sectors. He specializes in supporting OEMs, captives, and leasing companies across Europe with data-driven solutions for remarketing, valuation, and future value management. Prior to joining autobiz, Bertrand held various roles at PSA Bank, PSA Peugeot-Citroën, and Eurogroup Consulting. He holds a Master’s degree in Marketing from EDHEC Business School.
